Alnylam Announces FDA Approval of Supplemental New Drug Application for Oxlumo (lumasiran) in Advanced Primary Hyperoxaluria Type 1

Oxlumo Now Indicated for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary and Plasma Oxalate Levels in Pediatric and Adult Patients Approval is Based on Positive Efficacy and Safety Results of the ILLUMINATE-C Phase 3 Study of...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news